KDR and central nervous system cancer: A TAT-AT7 fusion protein designed by attaching the cell-penetrating peptide TAT to a vascular-targeting peptide AT7, competitively bound to VEGFR2 and NRP-1, preventing VEGFA165 binding and targeting glioma neovascularization in vivo [54].